The listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to substitute the much cheaper Semglee for Sanofi's Lantus without having to consult the prescribing healthcare professional.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3B13nw4
via IFTTT
0 comments:
Post a Comment